OQROGet OQRO Pro
Insider trade

Recursion Pharmaceuticals (RXRX)CFO sold ~$115K

Michael Secora, CFO at Recursion Pharmaceuticals, sold ~$115K of Recursion Pharmaceuticals shares.

~$115K
Approx. value · 15K sh @ $7.66
1.5M
Holds after · shares reported
Traded
Nov 13, 2024
Filed
Nov 15, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 1, 2024InsiderDirector sold ~$71K of RXRX shares in the open market
  2. Oct 2, 2024InsiderCEO sold ~$123K of RXRX shares in the open market
  3. Oct 3, 2024InsiderCEO sold ~$122K of RXRX shares in the open market
  4. Oct 8, 2024InsiderCFO sold ~$95K of RXRX shares in the open market
  5. Oct 9, 2024InsiderCFO sold ~$95K of RXRX shares in the open market
  6. Oct 15, 2024InsiderDirector sold ~$76K of RXRX shares in the open market
  7. Oct 24, 2024InsiderOfficer sold ~$38K of RXRX shares in the open market
  8. Oct 29, 2024InsiderDirector sold ~$77K of RXRX shares in the open market
  9. Nov 12, 2024Insider · 2 peopleInsiders: 2 sales (~$202K)
  10. Nov 13, 2024 · this disclosureInsiderCFO sold ~$115K of RXRX shares in the open market

What came next

  1. Nov 13, 2024InsiderCEO sold ~$155K of RXRX shares in the open market
  2. Nov 14, 2024InsiderCEO sold ~$147K of RXRX shares in the open market
  3. Dec 4, 2024InsiderCEO sold ~$143K of RXRX shares in the open market
  4. Dec 5, 2024InsiderCEO sold ~$142K of RXRX shares in the open market
  5. Jan 8, 2025InsiderCEO sold ~$146K of RXRX shares in the open market
  6. Jan 10, 2025InsiderCEO sold ~$141K of RXRX shares in the open market
  7. Feb 5, 2025InsiderCEO sold ~$154K of RXRX shares in the open market
  8. Feb 6, 2025InsiderCEO sold ~$162K of RXRX shares in the open market
  9. Mar 5, 2025InsiderCEO sold ~$132K of RXRX shares in the open market
  10. Mar 6, 2025InsiderCEO sold ~$127K of RXRX shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Recursion Pharmaceuticals

For Recursion Pharmaceuticals, OQRO holds 4 insider filings (SEC Form 4 or Form 144) and 4 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RXRX page.

Other recent filings by Michael Secora, Chief Financial Officer

The full history of Michael Secora, Chief Financial Officer is on the profile page.

How this filing works

Other disclosures at Recursion Pharmaceuticals

Everything OQRO holds on this company is on its RXRX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data